Mark M. Fuster

4.7k citations

49 papers · 3.1k indexed · 1 hit paper · h-index 23

Impact in

Cell Biology top 1%
- Proteoglycans and glycosaminoglycans research
Immunology and Allergy top 2%
- Cell Adhesion Molecules Research

Papers in

Cell Biology 16
- Proteoglycans and glycosaminoglycans research 16
Otorhinolaryngology 4

Co-authors: Jeffrey D. Esko Lianchun Wang P. Sriramarao Jillian R. Brown Roger Lawrence Manuela Schuksz Duc Ha Andrew L. Ries
Journals: Journal of Biological Chemistry (4 papers)Neoplasia (3 papers)Clinical Lung Cancer (3 papers)The Journal of Immunology (2 papers)Supportive Care in Cancer (2 papers)
Partner nations: United States China United Kingdom

In The Last Decade

Mark M. Fuster

49 papers receiving 3.0k citations

Hit Papers

align trajectories log scale

The sweet and sour of cancer: glycans as novel therapeutic targets 2005 · 1.1k citations

Peers

Countries citing papers authored by Mark M. Fuster

Since Specialization

Citations

This map shows the geographic impact of Mark M. Fuster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Fuster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Fuster more than expected).

Fields of papers citing papers by Mark M. Fuster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark M. Fuster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Fuster. The network helps show where Mark M. Fuster may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark M. Fuster, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark M. Fuster Line = papers co-authored together Mark M. Fuster links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeting glycan sulfation in a CD11c+ myeloid population inhibits early KRAS-mutant lung neoplasia Neoplasia ·So Young Kim, Xiaohui Fang, Purva Gupta, Nissi Varki, Mark M. Fuster	2021	2
2	Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomes Supportive Care in Cancer ·Duc Ha, Andrew L. Ries, Scott M. Lippman, Mark M. Fuster	2020	11
3	Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions Antiviral Research ·María C. Martín-Miguel, Weihua Jin, Amika Sood, David W. Montgomery, Oliver C. Grant, Mark M. Fuster, Li Fu, Jonathan S. Dordick, Robert J. Woods, Fuming Zhang, Robert J. Linhardt	2020	231
4	A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors After Curative-Intent Treatment American Journal of Physical Medicine & Rehabilitation ·Duc Ha, Jacqueline Kerr, Andrew L. Ries, Mark M. Fuster, Scott M. Lippman, James D. Murphy	2019	11
5	Time to treatment and survival in veterans with lung cancer eligible for curative intent therapy Respiratory Medicine ·Duc Ha, Andrew L. Ries, Lakshminarayan Ramesan, Florin Vaida, Eva Haukeland Fredriksen, Mark M. Fuster	2018	11
6	Heart Rate Recovery as a Preoperative Test of Perioperative Complication Risk The Annals of Thoracic Surgery ·Duc Ha, Mark M. Fuster, Andrew L. Ries, Peter D. Wagner, Peter J. Mazzone	2015	9
7	A General Method for Site Specific Fluorescent Labeling of Recombinant Chemokines PLoS ONE ·Tetsuya Kawamura, Bryan S. Stephens, Ling Qin, Xin Yin, Michael R. Dores, Thomas H. Smith, Neil Grimsey, Ruben Abagyan, JoAnn Trejo, Irina Kufareva, Mark M. Fuster, Catherina L. Salanga, Tracy M. Handel	2014	22
8	Stereotactic Body Radiation Therapy in Octogenarians With Stage I Lung Cancer Clinical Lung Cancer ·Ajay Sandhu, Steven Lau, Douglas A. Rahn, Sameer K. Nath, Daniel Kim, William Y. Song, Jontu Chandra Deb, Mark M. Fuster, Lyudmila Bazhenova, Arno J. Mundt	2013	36
9	Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer Radiotherapy and Oncology ·Sameer K. Nath, Ajay Sandhu, Daniel Kim, Mehmet Ömer Bostancı, L. L. CHEPEL, Joshua D. Lawson, Mark M. Fuster, Lyudmila Bazhenova, William Y. Song, Arno J. Mundt	2011	46
10	Endothelial Heparan Sulfate in Angiogenesis Progress in molecular biology and translational science ·Mark M. Fuster, Lianchun Wang	2010	71
11	Hypofractionated Radiotherapy as Definitive Treatment of Stage I Non-Small Cell Lung Cancer in Older Patients American Journal of Clinical Oncology ·Sherif El-Jayya, Ajay Sandhu, Mark M. Fuster, Karen Messer, Minya Pu, L. L. CHEPEL, Lyudmila Bazhenova, Stephen L. Seagren	2010	6
12	Heparan Sulfate Regulates VEGF165- and VEGF121-mediated Vascular Hyperpermeability Journal of Biological Chemistry ·Ding Xu, Mark M. Fuster, Roger Lawrence, Jeffrey D. Esko	2010	78
13	Deficiency of Endothelial Heparan Sulfates Attenuates Allergic Airway Inflammation The Journal of Immunology ·Riaz I. Zuberi, Xiao Na Ge, Shuxia Jiang, Nooshin S. Bahaie, Bit Na Kang, 公之古川, 理佐今村, Mark M. Fuster, Jeffrey D. Esko, P. Sriramarao	2009	40
14	Definitive Radiation Therapy for Stage I Non–Small-Cell Lung Carcinoma: Institutional Experience With Contemporary Conformal Planning Clinical Lung Cancer ·Ajay Sandhu, Karen Messer, Mark M. Fuster, Sherif El-Jayya, Minya Pu, Lyudmila Bazhenova, 勇吉東, Stephen L. Seagren	2009	3
15	Surfen, a small molecule antagonist of heparan sulfate Proceedings of the National Academy of Sciences ·Manuela Schuksz, Mark M. Fuster, Jillian R. Brown, Brett E. Crawford, 二郎速水, Roger Lawrence, Charles A. Glass, Lianchun Wang, Yitzhak Tor, Jeffrey D. Esko	2008	142
16	Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis The Journal of Cell Biology ·Mark M. Fuster, Lianchun Wang, Benshan Niu, Lyudmila Sikora, Krisanavane Reddi, Phillip H. A. Lee, Katherine A. Radek, Manuela Schuksz, Joseph R. Bishop, Richard L. Gallo, P. Sriramarao, Jeffrey D. Esko	2007	96
17	Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses Nature Immunology ·Lianchun Wang, Mark M. Fuster, P. Sriramarao, Jeffrey D. Esko	2005	395
18	Glycoside Decoys of Glycosylation. Trends in Glycoscience and Glycotechnology ·Jillian R. Brown, Mark M. Fuster, Jeffrey D. Esko	2001	7
19	Tumor attenuation by combined heparan sulfate and polyamine depletion Proceedings of the National Academy of Sciences ·Mattias Belting, Lubor Borsig, Mark M. Fuster, Jillian R. Brown, Lo Persson, Lars‐Âke Fransson, Jeffrey D. Esko	2001	103
20	Maturation of the Fast Component of Vestibular Nystagmus During Childhood and Young Adulthood Acta Oto-Laryngologica ·Mark M. Fuster, Behrad Moin Nezhad, Edward M. Ornitz	1994	3

About Mark M. Fuster

Mark M. Fuster is a scholar working on Cell Biology, Otorhinolaryngology, Radiation, Immunology and Allergy and Pulmonary and Respiratory Medicine, having authored 49 papers that have together received 3.1k indexed citations. Recurring topics across this work include Proteoglycans and glycosaminoglycans research (16 papers), Glycosylation and Glycoproteins Research (13 papers), Lung Cancer Diagnosis and Treatment (12 papers), Advanced Radiotherapy Techniques (7 papers), Lymphatic System and Diseases (5 papers), Angiogenesis and VEGF in Cancer (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer survivorship and care (4 papers). The work is most often cited by research in Cell Biology (937 citations), Immunology and Allergy (230 citations), Immunology (639 citations), Molecular Biology (1.9k citations) and Organic Chemistry (575 citations). Mark M. Fuster has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Jeffrey D. Esko, Lianchun Wang, P. Sriramarao, Jillian R. Brown, Roger Lawrence, Manuela Schuksz, Duc Ha, Andrew L. Ries, Ding Xu and Robert J. Woods. Their work appears in journals such as Journal of Biological Chemistry, Neoplasia, Clinical Lung Cancer, The Journal of Immunology and Supportive Care in Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact